| Early pattern | Active pattern | Late pattern | CSURI | VEGF-A |
---|---|---|---|---|---|
Females vs males | 6 (14.3 %) vs 0 (0 %) | 18 (42.9 %) vs 2 (100 %) | 18 (42.9 %) vs 0 (0 %) | 9.6 (0.14–80.0) vs 23.2 (19.0–27.5) | 0.49 (0.02–3.05) vs 0.25 (0.11–0.38) |
Diffuse vs limited | 1 (10 %) vs 5 (14.7 %) | 5 (50.0 %) vs 15 (44.1 %) | 4 (40 %) vs 14 (41.7 %) | 9.1 (2.4–50.5) vs 10.5 (0.14–80.0) | 0.42 (0.11–3.05) vs 0.49 (0.02–0.07) |
Anti-Scl70 vs ACA | 0 (0 %) vs 2 (9.1 %) | 5 (41.7 %) vs 11 (50 %) | 7 (58.3 %) vs 10 (45.4 %) | 11.4 (3.6–20.7) vs 11.9 (0.51–80.0) | 0.46 (0.13–1.14) vs 0.49 (0.02–1.70) |
Anti-Scl70 vs others | 0 (0 %) vs 4 (40 %) | 5 (41.7 %) vs 4 (40 %) | 7 (58.3 %) vs 1 (10 %) | 11.4 (2.4–50.5) vs 9.2 (0.14–27.5) | 0.46 (0.13–1.14) vs 0.43 (0.02–3.05) |
ACA vs others | 2 (9.1 %) vs 4 (40 %) | 11 (50 %) vs 4 (40 %) | 10 (45.4 %) vs 1 (10 %) | 11.9 (0.51–80.0) vs 9.2 (0.14–27.5) | 0.49 (0.02–1.7) vs 0.43 (0.11–3.05) |
No ulcers vs ulcers | 3 (10.3 %) vs 2 (13.3 %) | 13 (29.5 %) vs 7 (46.7 %) | 12 (41.4 %) vs 6 (40 %) | 11.9 (0.14–68.7) vs 9.1 (0.51–80.0) | 0.47 (0.02–3.05) vs 0.50 (0.11–1.14) |
No GE vs GE | 2 (22.2 %) vs 4 (11.4 %) | 4 (44.4 %) vs 16(45.7 %) | 3 (33.3 %) vs 15 (42.5 %) | 7.0 (0.51–68.7) vs 12.0 (0.14–80.0) | 0.37 (0.13–1.0) vs 0.49 (0.02–3.05) |
sPAP < 45 vs > 45 mmHg | 6 (14.6 %) vs 0 (0 %) | 20 (48.8 %) vs 0 (0 %) | 17 (41.4 %) vs 3 (100 %)* | 9.9 (0.14–80.0) vs 13 (3.9–15.1) | 0.49 (0.02–3.05) vs 0.28 (0.21–0.35) |
DLCO < 50 % vs > 50 % | 0 (0 %) vs 6 (15.8 %) | 2 (33.3 %) vs 18 (47.3 %) | 4 (66.6 %) vs 11 (28.9 %) | 5.9 (3.9–13.7) vs 11.3 (0.14–80.0) | 0.48 (0.28–1.14) vs 0.49 (0.02–3.05) |
FVC < 80 % vs > 80 % | 0 (0) vs 6 (16.2 %) | 3 (42.8 %) vs 17 (45.9 %) | 4 (57.1 %) vs 14 (37.8 %) | 9.1 (0.14–80.0) vs 13 (3.3–27.5) | 0.54 (0.02–3.05) vs 0.38 (0.11–1.0) |
No honeycombing vs honeycombing | 5 (12.8 %) vs 1 (20 %) | 19 (48.7 %) vs 1 (20 %) | 15 (38.4 %) vs 3 (60 %)* | 5.9 (0.14–80.0) vs 11.8 (5.1–15.1) | 0.34 (0.02–3.05) vs 0.68 (0.28–1.14) |
Skin score < 14 vs > 14 | 6 (16.2 %) vs 0 (0 %) | 16 (43.2 %) vs 4 (57.1 %) | 16 (43.2 %) vs 3 (42.8 %) | 10.9 (0.14–80.0) vs 5.5 (2.1–68.7) | 0.46 (0.02–1.7) vs 0.52 (0.11–3.05) |
No iloprost vs iloprost | 3 (15.8 %) vs 3 (12 %) | 11 (57.9 %) vs 9 (36 %) | 5 (26.3 %) vs 13 (52 %)* | 10.5 (0.51–68.7) vs 9.2 (0.14–80.0) | 0.38 (0.02–3.05) vs 0.49 (0.13–1.70) |
No bosentan vs bosentan | 6 (16.2 %) vs 0 (0 %) | 19 (51.3 %) vs 1 (14.2 %) | 12 (32.4 %) vs 6 (85.7 %)* | 10.9 (0.14–80.0) vs 8.3 (3.9–22.3) | 0.50 (0.02–3.05) vs 0.28 (0.21–0.58) |
Early pattern vs others | – | – | – | 4.2 (0.14–11.3) vs 11.2 (0.51–80.0) | 0.63 (0.02–0.77) vs 0.39 (0.11–3.05) |
Active pattern vs others | – | – | – | 5.9 (1.4–68.7) vs 12.1 (0.14–80.0) | 0.48 (0.11–3.05) vs 0.43 (0.02–1.07) |
Late pattern vs others | – | – | – | 13.7 (0.51–80.0) vs 5.9 (0.14–68.7)* | 0.35 (0.21–1.70) vs 0.58 (0.02–3.05) |
VEGF-A < 0.8U vs > 0.8U | 5 (13.5 %) vs 1 (14.3 %) | 16 (43.2 %) vs 4 (57.1 %) | 16 (43.2 %) vs 2 (28.5 %) | 10.2 (0.14–80.0) vs 9.0 (3.3–13.7) | – |
CSURI > 2.94 vs < 2.94 | 4 (11.1 %) vs 2 (25 %) | 15 (41.6 %) vs 5 (62.5 %) | 17 (47.2 %) vs 1 (12.5 %)* | – | 0.46 (0.02–3.05) vs 0.58 (0.13-0.71) |